Companies: 10,795·Total market cap: $144.5T
Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.

FOLDNASDAQHealthcare
$14.49
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio
52W High$14.5
52W Low$5.51
Overview

Amicus Therapeutics, Inc. (FOLD) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · FOLD · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.09fold eps ttm · fold earnings per shareEarnings history
PE Ratio (TTM)fold pe ratio ttm · fold price to earningsPE Ratio deep dive
Revenue (TTM)$634.2Mfold revenue ttm · fold annual revenueFull revenue history
Dividend YieldNo Dividenddoes fold pay dividends · fold dividend yieldDividend history
Shares Outstanding308.4Mfold shares outstanding · fold floatShares outstanding history
Next EarningsTBAfold earnings date · fold next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$634.2M▲ +20.05% YoY
202320242025
amicus therapeutics, inc. revenue · fold revenue 2025
FY 2025Net Income-$27.1M▲ +51.68% YoY
202320242025
amicus therapeutics, inc. net income · fold profit 2025
FY 2025EPS$-0.09▲ +51.17% YoY
202320242025
fold eps · amicus therapeutics, inc. earnings per share 2025
TTM:Revenue: $634.2MNet Income: -$27.1MEPS: $-0.09View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy24 analystsis fold a buy · fold analyst rating
Strong Buy
0
Buy
16
Hold
7
Sell
1
Strong Sell
0
12-Month Price Target
$14.50Low
$14.49Current
$14.50Avg Target0.07% upside
$14.50High
fold price target · fold 12 month forecast

Total: 24 · Buy rate: 66.7%

The FOLD analyst consensus is Buy, based on ratings from 24 Wall Street analysts over the past 3 months. The average 12-month price target is $14.50, representing +0.07% upside from the current price of $14.49.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.00%
3M+0.84%
YTD+1.76%
1Y+132.21%
5Y+61.00%

About Amicus Therapeutics, Inc.

CEOBradley L. Campbell
IPO DateMay 31, 2007
Employees499
CountryUS

Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orall…

what is amicus therapeutics, inc. · fold stock overview · amicus therapeutics, inc. company profile · who is amicus therapeutics, inc. ceo · fold NASDAQ · amicus therapeutics, inc. headquarters · amicus therapeutics, inc. business segments

About Stock Overview & Key Data

Amicus Therapeutics, Inc. (FOLD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 31, 2007. As of the latest trading session, FOLD stock price is $14.49, with a market capitalization of $4.5B. The stock has returned +132.21% over the past 12 months and +1.76% year-to-date.

According to 24 Wall Street analysts, the consensus rating for Amicus Therapeutics, Inc. stock is Buy, with an average 12-month price target of $14.50. In fiscal year 2025, Amicus Therapeutics, Inc. reported revenue of $634.2M and net income of -$27.1M. For detailed data — including Amicus Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Amicus Therapeutics, Inc. (FOLD) stock price is $14.49. The stock is traded on NASDAQ under the ticker symbol FOLD. The 52-week range is $5.51 – $14.50.

FOLD stock priceFOLD quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice